Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Capsaicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,516Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of December 4, 2024
    Enforcement Report - Week of December 4, 2024

    04 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-4-2024-4372.pdf

    FDA
    04 Dec 2024
    Share Share
    Enforcement Report - Week of September 13, 2023
    Enforcement Report - Week of September 13, 2023

    13 Sep 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-13-2023-60327.pdf

    FDA
    13 Sep 2023
    Share Share
    Enforcement Report - Week of March 15, 2023
    Enforcement Report - Week of March 15, 2023

    15 Mar 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-15-2023-86840.pdf

    FDA
    15 Mar 2023
    Share Share
    Initiator Pharma obtains approval to begin trial for pain-reducing effects
    Initiator Pharma obtains approval to begin trial for pain-reducing effects

    27 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/initiator-approval-trial-pain-reducing-effects/

    CLINICALTRIALSARENA
    27 Nov 2021
    Share Share
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA

    19 Dec 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/averitas-pharma-announces-fda-acceptance-of-snda-filing-for-qutenza-capsaicin-8-patch-for-the-treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-300976908.html

    PR NEWSWIRE
    19 Dec 2019
    Share Share
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)

    18 Dec 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/averitas-pharma-announces-fda-acceptance-of-snda-filing-for-qutenza-capsaicin-8-patch-for-the-treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-300976908.html

    PR NEWSWIRE
    18 Dec 2019
    Share Share